ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Profit from the Pros – Zacks Free Email Newsletter
Our free email newsletter is filled with timely stock picks and market commentary. Sign up for free. Already on board? Check out the archive.

Quote:

Search for Ticker

Free Membership

Search:

ATRC: Atricure Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

ATRICURE INC (NASD)
ATRC	5.65	-0.21	(-3.58%)	Vol. 18,324	15:47 ET

AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart.

General Information

ATRICURE INC

6033 Schumacher Park Drive West Chester, OH 45069 Phone: 513-755-4100 Fax: 513-755-4108 Web: www.atricure.com Email: ir@atricure.com

Industry	MED PRODUCTS
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	02/18/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	5.86
52 Week High	6.08
52 Week Low	1.00
Beta	1.68
20 Day Moving Average	47,560.30
Target Price Consensus	5.7

% Price Change
4 Week	37.76
12 Week	55.72
YTD	163.74

% Price Change Relative to S&P 500
4 Week	36.28
12 Week	46.81
YTD	118.28

Share Information
Shares Outstanding (millions)	14.99
Market Capitalization (millions)	87.78
Short Ratio	0.87
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.09
Current Year EPS Consensus Estimate	-0.34
Estimated Long-Term EPS Growth Rate	20.00
Next EPS Report Date	02/18/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	2.00
30 Days Ago	2.33
60 Days Ago	2.33
90 Days Ago	2.33

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	50.00%
vs. Previous Quarter	25.00%

Sales Growth
vs. Previous Year	-10.28%
vs. Previous Quarter:	-3.61%

Price Ratios
Price/Book	4.80
Price/Cash Flow	-
Price / Sales	1.66

ROE
09/30/09	-23.72
06/30/09	-24.00
03/31/09	-23.37

ROA
09/30/09	-15.29
06/30/09	-16.54
03/31/09	-17.05

Current Ratio
09/30/09	2.74
06/30/09	3.39
03/31/09	4.15

Quick Ratio
09/30/09	2.26
06/30/09	2.73
03/31/09	3.15

Operating Margin
09/30/09	-10.30
06/30/09	-11.55
03/31/09	-12.12

Net Margin
09/30/09	-32.97
06/30/09	-26.64
03/31/09	-26.37

Pre-Tax Margin
09/30/09	-32.97
06/30/09	-26.64
03/31/09	-26.37

Book Value
09/30/09	1.22
06/30/09	1.50
03/31/09	1.55

Inventory Turnover
09/30/09	2.12
06/30/09	2.15
03/31/09	2.23

Debt-to-Equity
09/30/09	0.17
06/30/09	0.16
03/31/09	0.00

Debt to Capital
09/30/09	14.45
06/30/09	13.94
03/31/09	0.09


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research